Persson B, Slezak P, Efendic S, Häggmark A
Department of Diagnostic Radiology, Karolinska Hospital, Stockholm, Sweden.
Hepatogastroenterology. 1992 Jun;39(3):259-61.
In a double-blind randomized study, 30 patients received somatostatin infusion during ERCP and 30 patients placebo with the aim of evaluating whether somatostatin can reduce the incidence of injection pancreatitis. S-amylase, U-amylase and S-lipase were evaluated before, during and after (up to 48 hours) ERCP. C-peptide was also determined as a marker of the function of the endocrine pancreas. While no statistically significant effect of somatostatin in terms of amylase and lipase was to be found, somatostatin did significantly decrease c-peptide levels in plasma, indicating that the peptide inhibited beta-cell secretion. About 40% of patients in the somatostatin group and about 50% in the placebo group showed signs of injection pancreatitis (elevated levels of enzymes) and in both groups there are patients with clinically apparent pancreatitis.
在一项双盲随机研究中，30例患者在ERCP期间接受生长抑素输注，30例患者接受安慰剂，目的是评估生长抑素是否能降低注射性胰腺炎的发生率。在ERCP之前、期间和之后（长达48小时）评估血清淀粉酶、尿淀粉酶和血清脂肪酶。还测定了C肽作为内分泌胰腺功能的标志物。虽然未发现生长抑素在淀粉酶和脂肪酶方面有统计学上的显著作用，但生长抑素确实显著降低了血浆中的C肽水平，表明该肽抑制了β细胞分泌。生长抑素组约40%的患者和安慰剂组约50%的患者出现注射性胰腺炎的体征（酶水平升高），且两组均有临床明显胰腺炎的患者。
